Diagnostic Test Kits for Dengue Virus Detection Evaluated
By LabMedica International staff writers Posted on 28 Oct 2014 |
Image: An enzyme-linked immunosorbent assay (ELISA) kit for dengue virus NS1 antigen (Photo courtesy of Diagnostic Automation Inc.).
Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect immunoglobulin M (IgM) antibodies to Dengue virus or the virus genome.
Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.
An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.
A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).
The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.
The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.
An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.
A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).
The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.
The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form